Targeting Inhibition of EGFR Reverses the Malignant Behavior of Osteosarcoma

XIANG Huaxia^1,2, KANG Quan^1,2, LI Zhipeng^1,2, LUO Qing^1,2^*

(¹Department of Hepatology, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China; ²Laboratory of Stem Cell Biology and Therapy, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorder, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China)

Abstract:

The aim of this work was to investigate the malignant behavior changes of osteosarcoma. These osteosarcoma cells were infected with adenovirus which can express recombinant anti-epidermal growth factor receptor variant III (EGFRvIII) single-chain variable fragment (scFv) antibody. This kind of antibody can inhibit EGFRvIII in osteosarcoma cells. We harvest the recombinant adenovirus to infect osteosarcoma cells 143B, MG63, TE85. In vitro, MTT, crystal violet staining, cell scratch assay, cell assay, cell migration, matrigel experiment methods were used to investigate the changes of tumor malignant behaviors such as proliferation, adhesion, migration and invasion of osteosarcoma cell. In vivo, we built animal models of osteosarcoma which were treated by targeted inhibition of EGFR and then detected the tumor growth by using Xenogen imaging analysis. The malignant behaviors of osteosarcoma 143B, MG63, TE85 were significantly inhibited after inhibiting EGFRvIII. Xenogen imaging results indicate that the growth of tumor is slowing down. The malignant behaviors of osteosarcoma could be significantly decreased and reversed after inhibiting EGFRvIII in osteosarcoma cells in vitro. And also the growth ability of tumor cell proliferation may be significantly decreased after inhibiting EGFRvIII in vivo. EGFRvIII may be the very promising new treatment target of osteosarcoma in the future.

CSTR: 32200.14.cjcb.2019.11.0010